Hims & Hers Health, Inc. HIMS R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.hims.com

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Market & Price

Market Cap

$6.05B

Current Price

$26.15

High / Low (52W)

$66.18 / $14.52

Beta

2.42

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

20.32

PEG Ratio

2.15

Book Value

$2.38

Price to Book

10.99

P/S

2.55

EV/EBITDA

77.13

Dividend Yield

Profitability & Returns

ROCE

6.03%

ROE

-2.66%

ROA

0.60%

Profit Margin

-0.56%

Op Margin

-7.90%

EPS (Latest Qtr)

$-0.40

EPS (TTM)

$-0.09

Balance Sheet & Liquidity

Debt/Equity

2.54

Quick Ratio

1.46

Current Ratio

1.69

Debt

$1.13B

Total Assets

$2.15B

Current Assets

$767.64M

Working Capital

$363.21M

Ownership

Promoter Holding

5.43%

Chg in Prom Hold

FII / Inst Holding

69.96%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$6.43B

Total Revenue (TTM)

$2.37B

EBITDA

$83.42M

Free Cash Flow

$174.31M

Operating Cash Flow

$280.27M

Shares Outstanding

223.08M

Gross Margin

72.92%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

64.55%

Profit 5Y

98.48%

Revenue (YoY)

3.80%

Earnings (YoY)

PROS

Compounding revenue at 64.5% over 5 years.
Profit CAGR of 98.5% over 5 years.
Generates positive free cash flow.

CONS

Trading 60.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	HIMS Hims & Hers Health, Inc. R2K	26.15	-	$6.05B	-	6.03%	-2.66%	64.55%	98.48%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	30.06M	35.90M	41.32M	52.31M	60.69M	74.17M	101.31M	113.56M	144.84M	190.77M	207.91M	226.70M	278.17M	315.65M	401.56M	586.01M	544.83M	598.98M	617.82M	608.10M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	155.32M	128.64M	156.92M	173.38M	211.32M
Gross Profit	-	-	20.62M	25.66M	31.28M	40.25M	47.28M	54.87M	74.76M	87.18M	114.45M	153.43M	170.16M	187.31M	229.09M	256.61M	317.89M	430.69M	416.20M	442.06M	444.44M	396.79M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	372.79M	389.47M	430.25M	435.25M	475.11M
Operating Income	-16.61K	-449.94K	-6.22M	-979.00K	-3.32M	-48.41M	-17.41M	-27.66M	-16.92M	-20.19M	-19.98M	-11.26M	-9.24M	-8.55M	9.90M	11.03M	22.37M	57.90M	26.72M	11.81M	9.19M	-78.32M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	66.17M	37.19M	29.48M	27.28M	-56.37M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60.49M	32.85M	12.22M	18.35M	-101.55M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.01M	-9.65M	-3.55M	-2.25M	-9.44M
Net Income	-16.61K	436.05K	-6.03M	-981.00K	-5.87M	-51.40M	-9.15M	-15.94M	-16.25M	-19.68M	-18.84M	-10.07M	-7.16M	-7.57M	11.13M	13.30M	75.59M	49.48M	42.51M	15.77M	20.60M	-92.11M
Diluted EPS	-	-	-0.17	-0.03	-0.16	-0.34	-0.05	-0.08	-0.08	-0.10	-0.09	-0.05	-0.03	-0.04	0.05	0.06	0.32	0.20	0.17	0.06	0.08	-0.40

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	82.56M	148.76M	-	526.92M	872.00M	1.48B	2.35B
Cost of Revenue	-	-	-	118.19M	157.05M	303.38M	614.26M
Gross Profit	44.60M	109.45M	-	408.72M	714.95M	1.17B	1.73B
Operating Expenses	-	-	-	477.42M	744.40M	1.11B	1.63B
Operating Income	-74.41M	-15.14M	-	-68.70M	-29.45M	61.90M	105.61M
EBITDA	-	-	-	-61.22M	-19.94M	78.99M	160.12M
Interest Expense	-	-	0	-	-	-	-
Pretax Income	-	-	-	-65.71M	-21.57M	71.71M	123.92M
Tax Provision	-	-	-	-31.00K	1.98M	-54.33M	-4.44M
Net Income	-72.06M	-18.11M	-	-65.68M	-23.55M	126.04M	128.37M
Diluted EPS	-2.07	-0.51	-	-0.32	-0.11	0.53	0.51

Compounded Sales Growth

5 Years:	64.55%
1 Year:	3.80%

Compounded Profit Growth

5 Years:	98.48%
1 Year:	-

Stock Price Performance

1 Year:	-53.77%
6 Months:	-29.50%
3 Months:	+80.10%
1 Month:	-0.68%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	204.77M	118.70M	-	366.34M	441.19M	707.54M	2.15B
Current Assets	-	-	-	-	-	216.59M	265.05M	395.83M	767.64M
Cash & Equivalents	-	-	1.51M	27.34M	-	46.77M	96.66M	220.58M	228.62M
Inventory	-	-	-	-	-	21.56M	22.46M	64.43M	80.13M
Receivables	-	-	-	-	-	3.23M	6.75M	6.08M	32.15M
Total Liabilities	-	-	8.17M	15.61M	-	54.60M	97.16M	230.82M	1.61B
Current Liabilities	-	-	979.39K	15.23M	-	47.94M	88.47M	221.37M	404.43M
Long Term Debt	-	-	-	-	-	-	-	-	972.58M
Total Debt	-	-	-	-	-	5.31M	9.95M	11.35M	1.12B
Total Equity	-71.36M	0	-139.79M	-146.87M	-	311.74M	344.03M	476.72M	540.93M
Shares Outstanding	-	-	-	-	-	208.43M	213.48M	220.84M	227.25M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-74.87M	-2.48M	-	-26.53M	73.48M	251.08M	300.01M
Investing Cash Flow	-39.30M	-39.70M	-	34.70M	-12.11M	-19.05M	-1.02B
Financing Cash Flow	95.32M	47.74M	-	-33.13M	-11.47M	-107.84M	729.62M
Capital Expenditure	-	-	-	-7.25M	-26.49M	-52.75M	-242.59M
Free Cash Flow	-	-	-	-33.78M	46.99M	198.33M	57.41M
Net Change in Cash	-	-	-	-24.96M	49.90M	124.19M	4.67M
Share Buybacks	0	0	0	0	2.00M	83.04M	89.96M

Ratios (Annual)

Figures in %.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	54.0%	73.6%	-	77.6%	82.0%	79.5%	73.8%
Operating Margin %	-90.1%	-10.2%	-	-13.0%	-3.4%	4.2%	4.5%
Net Margin %	-87.3%	-12.2%	-	-12.5%	-2.7%	8.5%	5.5%
ROE %	51.6%	12.3%	-	-21.1%	-6.8%	26.4%	23.7%
ROCE %	-36.5%	-14.6%	-	-21.6%	-8.4%	12.7%	6.0%

Shareholding Pattern

Insiders

5.43%

Institutions

69.96%

Public Float

73.98%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	11.81%	26.34M	$688.72M
2	Vanguard Portfolio Management LLC	4.57%	10.18M	$266.31M
3	Vanguard Capital Management LLC	4.19%	9.34M	$244.23M
4	Morgan Stanley	3.98%	8.89M	$232.45M
5	State Street Corporation	3.34%	7.46M	$195.08M
6	Defiance Etfs, LLC	3.33%	7.42M	$194.14M
7	JPMORGAN CHASE & CO	2.35%	5.24M	$137.05M
8	Geode Capital Management, LLC	2.33%	5.20M	$135.95M
9	Bank of America Corporation	1.95%	4.36M	$113.95M
10	UBS Group AG	1.86%	4.15M	$108.57M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HIMS

No recent headlines available.

HIMS · Healthcare